- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00974636
Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial (BIA)
ABSTRACT
Background:
It is well recognized that excess dietary salt intake plays a major role in the development of hypertension. Chronic Kidney Disease (CKD) is associated with excess salt and water retention (excess volume) which is associated with hypertension.
Hypotheses:
Hypothesis 1:
Dietary salt restriction will improve volume status in subjects with CKD stages 3-4 as assessed by Bioelectrical Impedance Analysis (BIA).
Hypothesis 2:
Dietary salt restriction will result in improved blood pressure control in patients with CKD stages 3-4.
Hypothesis 3:
Dietary salt restriction will decrease albuminuria in patients with CKD stages 3-4.
Patients and Trial Design: This randomized crossover pilot study is designed to assess the effect of salt restriction on volume status in patients with CKD stages 3 and 4.
Subjects will be randomized to a treatment order: (1) 4 weeks of salt restriction of <85 mmol sodium per day, a 2 week washout period, and 4 weeks of usual salt diet, OR (2) 4 weeks of usual diet, 2 weeks washout, and 4 weeks of salt restriction. Patients will receive dietary counseling in person at each study visit and at weekly intervals by phone calls from study dieticians. At weeks 0, 4, 6 and 10, patients will undergo assessments for (i) physical examination with assessments for weight, blood pressure, pulse, anthropometrics and a standardized clinical assessment of volume status. (ii) volume status using bioelectrical impedance analysis (BIA) (iii) 24-hour urine testing for, albumin, creatinine and aldosterone Every 2 weeks throughout the study, a 24-hour urine sodium will be measured for compliance, and serum electrolytes will be assessed for safety.
Data Analysis: BIA measurements in the low salt group will be compared with the regular diet group using the standard linear model analysis for 2x2 crossover trials. Additionally, 24-hour ambulatory and static blood pressure and 24-hour urine aldosterone levels will be compared between the two groups.
Future Implications: A significant reduction in the degree of volume expansion (as assessed by BIA) and blood pressure as a result of a salt restricted diet would have implications for renal and cardiovascular protection and would warrant confirmation by a larger randomized trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals eligible to participate in this study must meet all of the following criteria:
- Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
- Age ≥ 18 years and ≤ 85 years.
- Willing and able to comply with all study procedures.
- Patients with eGFR of 20 to 60 ml/min/173m2 by the abbreviated (4-variable) MDRD equation and a relatively stable clinical course.
- Sitting systolic blood pressure ≥ 100 mmHg prior to study entry (to exclude people at risk from hypotension from dietary salt reduction).
Exclusion Criteria:
Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:
- Recent acute illness (≤1 month). Minor ailments such as a recovered common cold or allergic rhinitis would not be considered as exclusion criteria but would be left to the site PI's discretion.
- Recent hospitalization (≤1 month) unless clearly for a minor elective procedure unlikely to interfere with BIA measurements. The final decision will be left to the site PI's discretion.
- Any psychological condition (including alcoholism) that could interfere with the patient's ability to comply with the study protocol.
- Subjects with baseline 24-hour urinary sodium excretion ≤100 mmol/day.
- Amputation of a limb other than fingers or toes.
- Pacemaker, defibrillator, implantable pump, artificial joint, pins, plates or other types of metal objects in the body (other than dental fillings).
- Coronary stents or metal suture material in the heart.
- Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
- Weight over 300 pounds (limitation for examination table).
- Pregnancy or lactation.
- Patients with kidney diseases known to be associated with salt wasting (see above).
- Patients with atrial fibrillation as ambulatory blood pressure measurements may not be accurate in this setting.
- Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Salt Diet
Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
|
Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
Other Names:
|
Placebo Comparator: Ususal Salt Diet
Usual salt intake (approximately >180-200 mmol/day in the average American diet).
|
Usual salt intake (approximately >180-200 mmol/day in the average American diet).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary Outcome: Change in volume status (intracellular, extracellular volume, and total body water) as measured by BIA using both whole body and segmental techniques
Time Frame: 12 Weeks
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rajiv Saran, MD, University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00016384
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
AbbottTerminatedEnd-Stage Kidney DiseaseUnited States
-
European Society of Intensive Care MedicineCompletedAcute Kidney Injury | Renal Replacement Therapy | Chronic End Stage Kidney DiseaseBelgium
-
University of North Carolina, Chapel HillLantheus Medical ImagingCompletedChronic Kidney Diseases | Cystic Kidney DiseaseUnited States
Clinical Trials on Low Salt Diet
-
University of Southern DenmarkOdense University Hospital; Beckett Foundation; Danish Diabetes AcademyCompleted
-
Brigham and Women's HospitalTerminatedAutoimmunity | Sodium Chloride | Salt Intake | Th17 Helper Immune CellsUnited States
-
Vanderbilt UniversityCompleted
-
Vanderbilt University Medical CenterCompletedObesity | Cardiovascular Risk Factor | Salt; ExcessUnited States
-
Aga Khan UniversityWellcome TrustUnknown
-
Wolfson Medical CenterUnknown
-
Hospital Clínico Universitario de ValladolidUnknown
-
Josip Juraj Strossmayer University of OsijekRecruitingPsoriasis VulgarisCroatia
-
Bangkok Metropolitan Administration Medical College...Science research and innovationCompleted
-
University Hospital, GenevaCompleted